Session Title: Free Paper Session 23: Vascular Diseases & Diabetic Retinopathy VI
Session Date/Time: Sunday 10/09/2017 | 08:00-09:30
Paper Time: 08:36
Venue: Room 120
First Author: : Y.Louati SWITZERLAND
Co Author(s): : C. Bergin S. Ezziat P. de Gottrau V. Vaclavik
To report, mean IOP, number of antiglaucoma medication, duration of antiglaucoma treatment, time before anti-VEGF switch and reasons for switch as well as mean CMT at 1 week, 1 month, 4 months after Ozurdex® in BRVO/ CRVO.
Retrospective study of 28 eyes treated with dexamethasone implant for macular edema secondary to CRVO/BRVO
Obervational study. All eyes treated with Ozurdex® in the Ophthalmology Department, Fribourg Canton Hospital, Switzerland, were identified over a period of 6 months. BRVO and CRVO cases were selected. IOP, CMT (Optical coherence tomography (OCT)), number of antiglaucoma medication at baseline, 1 week,1 month 4 months after Ozurdex®, as well as time before anti-VEGF switch and reasons for switch were identified both retrospectively and prospectively. Number of total Ozurdex® per eye was searched for.
84 Ozurdex® injections performed. 66 Cases with BRVO/ CRVO were identified and selected, 18 were excluded (14 diabetic, 3 uveitic, 1 post-surgery macular edema). IOP went up at 1 week and 1 month but returned to baseline values at 4 months in both BRVO and CRVO. 3 eyes reached an IOP > 30 mmHg. No case of filtering surgery has been observed. Eyes treated with > 1 Ozurdex® quickly droped from 66 to 16 (2 IVT) , 11 (3IVT), 6 (4 IVT), 4 (5 IVT) and 1 (IVT). 12 were treated with antiglaucoma drops. 3 were under monotherapy, 6 under bitherapy, 2 under tritherapy and 1 under quadritherapy. Duration varied from 1 month to 21 months. No lifetime treatment was needed. 20 were switch to anti-VEGF. Reasons for switch were: HTIO, cataract acceleration, rubeosis, insurance problems, endophtalmitis suspicion, refusal to do more injections. 3 eyes already diagnosed with cataracts before Ozurdex® treatment needed phaco during the study.
Modest elevation of mean IOP was observed at 1 week and 1 month in 37% of eyes. Stable IOP at 4 months was demonstrated, treated if required. Exaggerated fear for IOP elevation after Ozurdex® leaded to quick discontinuation of Ozurdex® therapy and switch to anti-VEGF.